Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease

Journal of Neuroscience

Volumn 23, Issue 3, 2003, Pages 961-969

  Cepeda, Carlos ^a   Hurst, Raymond S ^a,c   Calvert, Christopher R ^a   Hernández Echeagaray, Elizabeth ^a   Nguyen, Oanh K ^a   Jocoy, Emily ^a   Christian, Lindsey J ^a   Ariano, Marjorie A ^b   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b The Chicago Medical College   (United States)

^c PFIZER INC   (United States)

Author keywords

Corticostriatal pathway; EPSCSs; Glutamatergic activity; Huntington's disease; Mouse models; R6 2

Indexed keywords

4 AMINOPYRIDINE; BICUCULLINE; GLUTAMIC ACID; RILUZOLE; SYNAPTOPHYSIN; TETRODOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; EXCITATORY POSTSYNAPTIC POTENTIAL; HUNTINGTON CHOREA; MOUSE; NERVE CELL NECROSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0037322570     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-03-00961.2003     Document Type: Article

References (52)

1. Ariano MA, Aronin N, DiFiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS (2002) Striatal neurochemical changes in transgenic models of Huntington's disease. J Neurosci Res 68:716-729.
2. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125:1908-1922.
3. Biziere K, Coyle JT (1979) Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. J Neurosci Res 4:383-398.
4. Calabresi P, Picconi B, Saulle E, Centonze D, Hainsworth AH, Bernardi G (2000) Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke 31:766-772.
5. Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G (2001) Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 21:5110-5120.
6. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257.
7. Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS (1998) Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol 79:82-94.
8. Cepeda C, Ariano MA, Calvert CR, Flores-Hernández J, Chandler SH, Leavitt BR, Hayden MR, Levine MS (2001a) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66:525-539.
9. Cepeda C, Hurst RS, Altemus KL, Flores-Hernandez J, Calvert CR, Jokel ES, Grandy DK, Low MJ, Rubinstein M, Ariano MA, Levine MS (2001b) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85:659-670.
10. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA 95:6480-6485.
11. Chéramy A, Barbeito L, Godeheu G, Glowinski J (1992) Riluzole in hibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147:209-212.
12. Cherry SD, Steakley MA, Meade C, Del Mar N, Reiner A), Cantrell AR (2001) Voltage-gated calcium channels: a potential role in Huntington's disease (HD). Soc Neurosci Abstr 27:99.6.
13. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548.
14. DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13:286-289.
15. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
16. Flores-Hernández J, Galarraga E, Pineda JC, Bargas I (1994) Patterns of excitatory and inhibitory synaptic transmission in the rat neostriatum as revealed by 4-AP. J Neurophysiol 72:2246-2256.
17. Halpain S, Hipolito A, Saffer L (1998) Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J Neurosci 18:9835-9844.
18. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 96:8727-8732.
19. Jahn R, Schiebler W, Ouimet C, Greengard P (1985) A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 82:4137-4141.
20. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86:2667-2677.
21. Köhler C, Schwarcz R, Fuxe K (1978) Perforant path transections protect hippocampal granule cells from kainate lesion. Neurosci Lett 10:241-246.
22. Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR (1999) Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53:1000-1011.
23. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, Aronin N (2001) Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 21:9112-9123.
24. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, Chesselet MF (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58:515-532.
25. Liévens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP (2001) Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 8:807-821.
26. Liévens JC, Woodman B, Mahal A, Bates G (2002) Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci 20:638-648.
27. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 19:10428-10437.
28. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM (2002) Dysregulation ofgene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11:1911-1926.
29. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
30. McGeer EG, McGeer PL, Singh K (1978) Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res 139:381-383.
31. Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 76: 166-172.
32. Morton AJ, Leavens W (2000) Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res Bull 52:51-59.
33. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20:5115-5123.
34. NicNiocaill B, Haraldsson B, Hansson O, O'Connor WT, Brundin P (2001) Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur J Neurosci 13:206-210.
35. Orlando LR, Alsdorf SA, Penney Jr JB, Young AB (2001) The role of group I and group II metabotropic glutamate receptors in modulation of striatal NMDA and quinolinic acid toxicity. Exp Neurol 167:196-204.
36. Petersén A, Chase K, Puschban Z, DiFiglia M, Brundin P, Aronin N (2002) Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic model of Huntington's disease. Exp Neurol 175:297-300.
37. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ (1996) The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71:949-976.
38. Rasmussen A, Macias R, Yescas P, Ochoa A, Davila G, Alonso E (2000) Huntington disease in children: genotype-phenotype correlation. Neuropediatrics 31:190-194.
39. Rebec GV, Barton SJ, Ennis MD (2002) Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J Neurosci 22:RC202(1-5).
40. Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME (1999) Riluzole therapy in Huntington's disease (HD). Mov Disord 14:326-330.
41. Sapp E, Penney J, Young A, Aronin N, Vonsattel JP, DiFiglia M (1999) Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. J Neuropathol Exp Neurol 58:165-173.
42. Schiefer J, Landwehrmeyer GB, Luesse HG, Sprunken A, Puls C, Milkereit A, Milkereit E, Kosinski CM (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 17:748-757.
43. Segal M (1995) Dendritic spines for neuroprotection: a hypothesis. Trends Neurosci 18:468-471.
44. Tang K, Low MJ, Grandy DK, Lovinger DM (2001) Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci USA 98:1255-1260.
45. Testa CM, Friberg IK, Weiss SW, Standaert DG (1998) Immunohistochemical localization of metabotropic glutamate receptors mGluRla and mGluR2/3 in the rat basal ganglia. J Comp Neurol 390:5-19.
46. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 97:8093-8097.
47. Urbani A, Belluzzi O (2000) Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci 12:3567-3574.
48. Wang H, Pickel VM (2002) Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudateputamen nucleus. J Comp Neurol 442:392-404.
49. Wüllner U, Standaert DG, Testa CM, Landwehrmeyer GB, Catania MV, Penney Jr JB, Young AB (1994) Glutamate receptor expression in rat striaturn: effect of deafferentation. Brain Res 647:209-219.
50. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-Daspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33:849-860.
51. Ziff EB (1997) Enlightening the postsynaptic density. Neuron 19:1163-1174.
52. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:493-498.